Back to Ophthalmology

OUR EXPERTISE AND SERVICES AVAILABLE IN

Emerging Ophthalmology

Overview

Spherix’s coverage of emerging ophthalmology indications focuses on evolving markets where a paradigm shift is expected in the coming years.

Services Available

Prepping for the pipeline

  • Dry Age-Related Macular Degeneration / Geographic Atrophy (US)

Benchmarking new brand performance

  • Byooviz (Samsung Bioepis and Biogen) Ranibizumab Biosimilar (US)

  • FYB201 (Coherus BioSciences) Ranibizumab Biosimilar (US)*

*Pending approvals and launch

Gauging impact of disruptive events

  • Ophthalmology Biosimilars Today and Tomorrow (US)

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Emerging Ophthalmology Coverage